MIST Milestone Pharmaceuticals Inc
Company Analysis
Latest News
🔴 Milestone Pharmaceuticals is trading 5% down today as Treasury yields stoke rate concerns
Milestone Pharmaceuticals is trading 5.06% down now at $0.82 amid broader risk-off pressure driven by elevated Treasury yields and renewed interest-rate...
🔴 Milestone Pharmaceuticals is trading 5% down today amid broad risk-off sentiment
Milestone Pharmaceuticals is trading at $0.87 (-5.02%), with broader risk-off sentiment likely contributing. - On September 23, 2026, no fresh...
🟢 Milestone Pharmaceuticals is trading 5.48% up in pre-market amid broader risk-on sentiment
Milestone Pharmaceuticals is trading 5.48% up in pre-market at $0.97, after rising from the September 17 close of $0.92 amid constructive broader-market...
🟢 Milestone Pharmaceuticals is trading 5.33% up in after-hours trading with no clear catalyst identified
Milestone Pharmaceuticals is trading 5.33% up at $1.00 after-hours, with no clear catalyst identified. - This compares with the September 14 regular-session...
🟢 Milestone Pharmaceuticals is trading 5% up in pre-market
Milestone Pharmaceuticals is trading at $1.03 (+5.09%), with the catalyst uncertain. - No new company-specific announcement or analyst action was identified...
🔴 Milestone Pharmaceuticals is trading 5.51% down today
Milestone Pharmaceuticals is trading 5.51% down at $0.99, with no clearly reported company-specific catalyst identified for the decline. - No new...
🔴 Milestone Pharmaceuticals is trading 5.7% down today as healthcare ETF falls 2.19%
Milestone Pharmaceuticals is trading 5.7% down at $1.13 as healthcare stocks broadly face pressure during the September 8, 2026 session. - Healthcare ETF is...
🟢 Milestone Pharmaceuticals is trading 6.61% up in pre-market after China’s NMPA approval of etripamil
Milestone Pharmaceuticals is trading at $1.29 (+6.61%) in pre-market after announcing China’s NMPA approval of etripamil nasal spray for adult PSVT on...
Milestone Pharma Secures China Approval for Etripamil, Triggering $2M Milestone Payment
Milestone Pharmaceuticals announced that its etripamil nasal spray has been approved by China’s National Medical Products Administration (NMPA) for the...
🟢 Milestone Pharmaceuticals is trading 5% up today on healthcare-sector strength
Milestone Pharmaceuticals is trading 5.08% up now at $1.24, compared with a September 2 close of $1.18, primarily supported by healthcare-sector strength and...
🟢 Milestone Pharmaceuticals is trading 5% up today after announcing new PSVT quality-of-life findings
Milestone Pharmaceuticals is trading 5.11% up now at $1.24 after announcing new longitudinal-study findings on how PSVT affects patients’ daily lives and...
🟢 Milestone Pharmaceuticals is trading 10.57% up today — no confirmed company-specific catalyst
Milestone Pharmaceuticals is trading 10.57% up at $1.15, with no confirmed company-specific catalyst explaining the August 25, 2026 move. - The latest...
🟢 Milestone Pharmaceuticals is trading 6.25% up today with no confirmed catalyst explaining the move
Milestone Pharmaceuticals is trading 6.25% higher at $1.10, with no confirmed company-specific catalyst identified. - The latest official release, dated...
Milestone Pharmaceuticals Advances Etripamil Phase 3 Trial, Shares Jump 3.9%
Milestone Pharmaceuticals enrolled the first patient in its Phase 3 ReVeRA-301 pivotal trial. The study evaluates etripamil nasal spray for the treatment of...
🔴 Milestone Pharmaceuticals is trading 5% down today as Treasury yields rise and U.S. indexes weaken
Milestone Pharmaceuticals is trading 5% down at $1.02, most likely reflecting broader risk-off conditions as Treasury yields rise and major U.S. indexes...
🟢 Milestone Pharmaceuticals is trading 5% up in pre-market amid healthcare-sector momentum, with XLV up 1.55%
Milestone Pharmaceuticals is trading at $1.14 (+5.11%), with the move apparently mainly supported by healthcare-sector momentum and XLV up 1.55% pre-market. -...
🟢 Milestone Pharmaceuticals is trading 5.66% up in pre-market with no clear overnight catalyst identified
Milestone Pharmaceuticals is trading 5.66% higher now at $1.16 after rising from the August 14, 2026 close of $1.10; no clear overnight catalyst has been...
🔴 Milestone Pharmaceuticals is trading 14.89% down today after missing second-quarter revenue and loss estimates
Milestone Pharmaceuticals is trading 14.89% down now at $1.08 after its August 12, 2026 second-quarter report missed Wall Street expectations. • Product...
Milestone Pharmaceuticals second quarter 2026 revenue missed estimates despite expanding CARDAMYST insurance coverage
Milestone Pharmaceuticals reported second quarter 2026 results characterized by a miss on both top and bottom lines as the company continues the initial...
Milestone Pharma Drops 16% Ahead of Earnings — Can a Nascent Heart Drug Justify the Cash Burn?
Shares of Milestone Pharmaceuticals plunged 15.7% to $1.07 in pre-market trading on August 12, moments before the company is set to release second-quarter...